anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Subjects with end stage renal disease, not yet on dialysis. eGFR (by MDRD equation) range \< 15 mL/min/1.73 m2 as determined at Screening.
— It is recommended that duloxetine delayed-release capsules should ordinarily not be administered to patients with any hepatic insufficiency [ ]. Hepatic Insufficiencysee Warnings and Precautions ( ) and Use in Specific Populations ( ) 5.148.9

— Duloxetine delayed-release capsules are not recommended for patients with end-stage renal disease or severe renal impairment (estimated creatinine clearance < 30 mL/min) [ ]. Severe Renal Impairmentsee Warnings and Precautions ( ) and Use in Specific Populations ( ) 5.148.10

— No dose adjustment is recommended for elderly patients on the basis of age. As with any drug, caution should be exercised in treating the elderly. When individualizing the dosage in elderly patients, extra care should be taken when increasing the dose [ ]. Elderly Patientssee Use in Specific Populations ( ) 8.5

— There are no adequate and well-controlled studies in pregnant women; therefore, duloxetine delayed-release capsules should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus [ ]. Pregnant Womensee Use in Specific Populations ( ) 8.1

— Because the safety of duloxetine in infants is not known, nursing while on duloxetine delayed-release capsules is not recommended [ ]. Nursing Motherssee Use in Specific Populations ( ) 8.3
Neuromuscular electrical stimulation (NMES) was applied on wrist and finger extensors for 30 minutes, 3 sessions per week for 8 weeks. The main electrostimulation parameters consisted of low-frequency current, a stimulation frequency of 35 Hz, symmetrical rectangular biphasic wave, and pulse duration of 300 μs.
Systems and methods for training an artificial intelligence-based system using self-supervised learning are provided. For each respective training medical image of a set of unannotated training medical images, the following steps are performed. A first augmented image is generated by applying a first augmentation operation to the respective training medical image. A second augmented image is generated by applying a second augmentation operation to the respective training medical image. A first representation vector is created from the first augmented image using an encoder network. A second representation vector is created from the second augmented image using the encoder network. The first representation vector is mapped to first cluster codes. The second representation vector is mapped to second cluster codes. The encoder network is optimized using the first and second representation vectors and the first and second cluster codes.
This is a Phase IIa multi-center, randomized, single-blind, placebo-controlled, crossover study in subjects with mild to moderate dementia due to Alzheimer's disease. Only the subject and their caregiver will be blinded to the study treatment. The study will consist of two cohorts of subjects (20 subjects per cohort), randomized in a 1:1 allocation to receive active study drug or placebo. Cohort 1 will receive a single intravenous dose of hMSCs of 1.5 million cells per kilogram body weight on their Study Day 1, and Cohort 2 will receive equal volume of Lactated Ringer's Solution on their Study Day 1. At the six-month time point for each subject after their first infusion, Cohort 1 will receive a single intravenous dose of Lactated Ringer's Solution and Cohort 2 will receive a single intravenous dose of hMSCs at 1.5 million cells per kilogram of the subject's body weight. Approximately 40 subjects will be enrolled in this study. An independent Data and Safety Monitoring Board will conduct periodic safety reviews.
NEW MATERIAL:A monoclonal antibody showing specificity to new lymphokine II, having the following physical and chemical properties. Molecular weight: 20,000+ or -2,000. Solubility: soluble in water, sodium chloride injection, slightly soluble or insoluble in ethyl ether, etc. Action: showing cell damaging activity against cell L929, showing neither inhibitory activity against multiplication of cell KD neither interferon activity. USE:A diagnosticum for human diseases, a ligand for affinity chromatography for preparing novel lymphokine II. PREPARATION:A warm-blooded animal except human is immunized against novel lymphokine II as an antigen, an antibody-forming cell is collected from the animal, and the cell is fused with a myeloid cell. Then, a fused cell capable of producing an anti-novel lymphokine II antibody is selected from the fused cell, it is multiplied, and the aimed formed antibody is collected. The novel lymphokine II is a novel substance, and it is obtained by treating a cell of leukocyte derived from human, capable of producting it, with an inducer.
Pulmonary emphysema, within the spectrum of Chronic Obstructive Pulmonary Disease (COPD), can be described as the destruction of alveolar walls and enlargement of the airspaces distal to the terminal bronchioles, with inflammatory infiltrate and no detectable fibrosis. Despite significant advances resulting from the introduction of new therapeutic approaches, such as pulmonary rehabilitation, an effective and not only palliative clinical treatment is yet to be achieved. Surgical treatment, in turn, involves highly complex procedures and, in the case of lung transplantation, the shortage of donors. In this context, cell therapy with stem cells is presented as a promising therapeutic alternative with great potential for applicability. The main goal of this study is to evaluate the safety of the infusion of bone marrow mononuclear cells (BMMC), adipose-derived stem cells (ASC), separately or conjugated, in COPD patients. The sample will consist of 20 advanced COPD patients (grade 3 by GOLD criteria). Patients will be, by lot, divided into four distinct groups, namely: Group 1: Control; Group 2: Bone marrow mononuclear cells; Group 3 - Stem cells derived from adipose tissue and Group 4: bone marrow mononuclear cells and stem cells derived from adipose tissue. After the selection of patients, clinical and laboratory evaluation will be conducted (cardiology, laboratory examinations and tests to define the score of dyspnea). The cells used for the cell therapy will be obtained from the patient's own bone marrow or adipose tissue (autologous). The separation of the bone marrow mononuclear (BMMC) will be performed by centrifugation in density gradient (Ficoll), while stem cells derived from adipose tissue will be isolated by enzymatic digestion (collagenase) and cultivation. The infusion will be performed by a peripheral vein (brachial) after preparation, separation, expansion and quality control of the cells. The patients will be followed for a period of 12 months. It is expected that this clinical protocol will allow an expansion in knowledge about cell therapy in pulmonary diseases and represents a significant step towards the establishment of new therapeutic approaches in COPD treatment.
Impaired Liver Function

Do not use Joyeaux in women with liver disease, such as acute viral hepatitis or severe (decompensated) cirrhosis of liver [see Contraindications (4)]. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue Joyeaux if jaundice develops.

Liver Tumors

Joyeaux is contraindicated in women with benign and malignant liver tumors [see Contraindications (4)]. Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases/100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage.

Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) COC users. However, the risk of liver cancers in COC users is less than one case per million users.
A therapeutic composition is described comprising a particulate dispersion of a hydrocolloid in a low water activity anti-microbial matrix. The composition may also contain any or all of a sequestrant, excipient, carrier and surfactant. The hydrocolloid may be naturally occurring, semisynthetic or synthetic. The invention extends to a method of producing a therapeutic composition. The composition is prepared by mixing a low water activity anti-microbial matrix with hydrocolloid particles at a temperature that will not cause degradation of the matrix. The method may also include the addition of other components such as excipients, sequestrants, carriers and surfactants and other agents. The invention extends to methods for treating a human or animal subject by applying or administering the composition to the subject subject in a therapeutically effective dose.
A purpose of the study is to evaluate an effect of evodiamine in combination with a chemotherapeutic agent on thyroid cancer cells. The present invention used TPC-1 and SW1736 thyroid cancer cells. Cell viability, cytotoxic activity, and cell death and migration are investigated by applying appropriate methods. In addition, drug combination analysis is performed. When evodiamine is treated, cell viability, and Bcl2 and phosphorylated-AKT protein levels are decreased, and cytotoxicity and the ratio of apoptotic cells are increased. When treated with wortmannin, cell viability and phosphorylation-AKT and Bcl2 protein levels are decreased, and cytotoxic activity is increased. In TGF-β-treated cells, evodiamine attenuated changes in morphology, growth, and migration, increased p21 and p53 protein levels, and decreased β-catenin, N-cadherin, vimentin, phosphorylated-AKT, MMP-2, and MMP-9 protein levels. When evodiamine and the chemotherapeutic agent are treated together, the combination indices are all less than 1.0. Therefore, evodiamine exhibits cytotoxicity in thyroid cancer cells, and inhibition of AKT enhances evodiamine-induced cytotoxicity. In addition, evodiamine inhibits the proliferation, migration, and epithelial-mesenchymal metastasis of thyroid cancer cells, and is synergized with the chemotherapeutic agent.
CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg / fortnightly) + Methylprednisolone \[500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75)\] without oral glucocorticoid (GC). From the third month, the group will receive only oral MMF (2-3 g) until the 6th month. Patients using GC ≤ 20 mg/day may enter the protocol with immediate reduction to 15 mg/day with a reduction of 5mg/month until complete withdrawal.
1,261,348. Composition comprising estriol. LEO A.B. 27 June, 1969 [2 April, 1968], No. 15852/68. Heading A5B. A composition suitable for topical application to a patient's scalp and hair comprises 0.02 to 1% by weight of estriol in a pharmaceutically and cosmetically acceptable solvent mixture, the mixture comprising water and an organic solvent having a boiling point not greater than 100C., and any organic solvent present having a boiling point greater than 100C being in a minor proportion by weight of the total organic solvent.
In this randomized controlled trial of the effects of chewing gum on body weight, we will randomly assign 200 overweight or mildly obese, but otherwise healthy adults (men and women, ages 19 to 50), to one of two groups: 1) a control group, which will receive printed information on optimal diet and increasing physical activity only, or 2) an intervention group, in which participants will be instructed to chew gum following meals and in place of snacks for a minimum of 90 minutes per day, in addition to receiving the same information on optimal diet and increasing physical activity as the control group. In this 8-week intervention, the primary outcome will be change in body weight, and secondary outcomes will be changes in body mass income (BMI), waist circumference, and blood pressure. Outcome measures will be assessed in both groups via clinic visits at baseline, 4 weeks post-randomization, and 8 weeks post-randomization. Adherence to the gum chewing protocol will be assessed at the clinic visits, as well as during telephone contacts at 2 weeks and 6 weeks post-randomization. The effects of the chewing gum intervention will be assessed by analysis of covariance (ANCOVA), wherein treatment assignment is the independent variable; the outcome measures described above will serve as dependent variables; and pre-randomization factors such as age, sex, and baseline BMI will be used as covariates. Our hypothesis is that those randomized to the intervention group will lowe more weight than those randomized to the control group.
FIELD: organic chemistry and chemical technology, pharmacy. SUBSTANCE: method of synthesis of the drug nitrazepam involves treatment of 2-chloro-5-nitrobenzoic acid with thionyl chloride to obtain 2-chloro-5-nitrobenzoic acid chloroanhydride. Then the latter is added to Friedel-Crafts reaction to obtain 2-chloro-5-nitro-benzophenone which then is aminated at 125-130 C by passing ammonia in the reaction mass under constant pressure 0.05-0.65 MPa to form 2-amino-5-nitrobenzophenone. Then the obtained compound is acetylated by treatment with chloroacetic acid chloroanhydride in toluene medium. Obtained 2-(2-chloroacet-amido)-5-nitrobenzophenone is converted to the crystalline end substance by cyclization with hexamethylenetetramine and 95-100% ethyl alcohol in the presence of ammonium chloride followed by treatment of reaction mass with concentrated sulfuric acid at mole ratio of indicated components = 1:(1.5-2.5):(16-54):(1.5-3): :(4-12), respectively, and acid neutralization. EFFECT: increased yield and quality indices of nitrazepam. 5 tbl, 7 ex
A double-blind, placebo-controlled ABPM study was conducted to evaluate the effects of milnacipran (up to 200 mg/day) on blood pressure in 321 fibromyalgia patients [see Warnings and Precautions (5.3)]. Information on heart rate was also collected. Following treatment with Savella 50mg BID for three weeks in patients who were normotensive at baseline, the mean increase in mean 24-hour heart rate from baseline was 13 beats per minute. After further treatment with Savella 100 mg BID for two weeks, the mean increase from baseline in heart rate was 13 beats per minute. 

Similar trends were observed in the clinical trials where Savella treatment was associated with mean increases in heart rate of approximately 7 to 8 beats per minute [see Adverse Reactions (6.1]. 

Increases in heart rate ≥ 20 beats per minute occurred more frequently in Savella-treated patients when compared to placebo (8% in the Savella 50 mg BID and 100 mg BID treatment arms versus 0.3% in the placebo arm). 

Savella has not been systematically evaluated in patients with a cardiac rhythm disorder. 

Measure heart rate prior to initiating treatment and periodically monitor the heart rate throughout Savella treatment. Treat pre-existing tachyarrhythmias and other cardiac disease before starting therapy with Savella. For patients who experience a sustained increase in heart rate while receiving Savella, either reduce the dose or discontinue treatment with Savella if clinically warranted.
The invention discloses a hand-cutting processing method for angelica sinensis decoction slices. The method comprises the following steps of: grinding heads, soaking and softening, steaming, pressing, peeling, slicing, drying, grading, boxing, casing and warehousing. The decoction of active ingredients of the angelica sinensis decoction slices processed by hand-cutting can be guaranteed, and raw materials cannot be wasted. According to the hand-cutting processing method, the angelica sinensis processing is led to standardization, so that the additional value of the angelica sinensis decoction slices is increased. The safe, effective, stable and controllable quality of the angelica sinensis decoction slices is guaranteed. The hand-cutting processing method can be used for guaranteeing the quality on a path that the angelica sinensis hand-cut decoction slices are led to the international market.
The anti-dementia medicine prepared from scutellaria barbata is invented for making up for a deficiency of clinical anti-dementia medicines. A series of experimental studies for years verify that the total flavone of the scutellaria barbata has obvious function of nerve protection, anti-dementia and memory improvement. The invention comprises the following steps of: pulverizing clean scutellaria barbata; carrying out the inverse flow of ethanol 20 times as much as the scutellaria barbata for 1 hour and filtering; carrying out the inverse flow of ethanol 20 times as much as dregs for 1 hour and filtering again; mixing the filtrate obtained twice; thoroughly recycling the ethanol after 60-DEG C decompression; adsorbing chlorophyll by adding 3% calcium carbonate to the residual liquid; standing for a night; carrying out suction filtration; regulating the filtrate to a pH value of 2 or so with acid; and obtaining the total flavone extract by centrifugal precipitation, 60-DEG C drying and the like. In the total flavone extract, the total content of the flavone is not less than 70% and can be prepared into tablets, capsules, oral liquid or injection. The Scutellaria barbata is abundant in nature or can be cultivated artificially with low cost, and the quality of the artificially-cultivated medicinal material is similar to the natural. The experiment proves that the anti-dementia medicine prepared from the total flavone of scutellaria barbata has positive clinical function, high efficiency and low toxicity, thereby having wide development foreground.
AAVrh74 was used as the vector for JWK007 injection. Because the Dystrophin gene is too large to be used for conventional rAAV loading (AAV packaging capacity \< 5.0kb), we independently designed a new micro-dystrophin (μDystrophin) for each functional domain of the gene. The protein includes structures essential for promoting neuronal nitric oxide synthase (nNOS) activity and membrane-binding domains.
Acute upper gastrointestinal bleeding is a common and potentially life-threatening condition. Non-variceal bleeding accounts for more than 80-90% of the cause with gastroduodenal peptic ulcer being the major cause. Endoscopic haemostasis has significantly improved the outcome of these patients. Recurrent bleeding remains one of the most important predictors of mortality. Previous studies have identified ulcers that are high risk for rebleeding.

Conventionally, endoscopic haemostasis is achieved by injection therapy, thermocoagulation or mechanical therapy such as haemostatic clips. However, there are limitations to thermo-coagulation and conventional haemostatic clips. Over the past few years, a novel endoscopic clipping device, the Over-The-Scope Clip (OTSC; Oversco Endoscopy AG, Tübingen, Germany) has become available. The device provides a robust and strong tissue apposition. The system was developed to close perforations and treat bleeding in the gastrointestinal tract. In chronic ulcers, an anchor device can be used to pull the ulcer base toward the aspiration cap to facilitate accurate clip application. With a larger jaw width and greater strength, the OTSC is expected to have superior haemostatic properties when compared to hemo-clips. Case series have been published on the clinical experience of OTSC on gastrointestinal bleeding with promising results.

Therefore, in this randomised controlled trial, we aim to compare the efficacy of the OTSC to standard endoscopic therapy in primary treatment of patients with peptic ulcer bleeding that are of high-risk for rebleeding. The hypothesis is that the use OTSC can significantly decrease the rebleeding rate in this group of patients.
OBJECTIVES: Adenoid cystic carcinoma (ACC) of the salivary glands has poor long-term prognosis and a high metastatic rate. Toll-like receptors (TLRs), first-line immune activators, have been associated with both tumor progression and suppression. We aimed to study TLR3 and TLR7 behavior in ACC.
MATERIALS AND METHODS: We studied TLR3 and TLR7 immunoexpression of 46 minor salivary gland ACCs diagnosed at the Department of Otorhinolaryngology - Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland over the period 1974-2012. The associations of TLR3 and TLR7 immunoexpression with clinicopathological factors were evaluated by χ2-test and Fisher's exact test.
RESULTS: In the majority of samples, both TLR3 and TLR7 were immunoexpressed in cytoplasm. The immunoexpression was heterogeneous between individual tumors. Stronger TLR7 immunoexpression associated with recurrence rate and poorer disease-specific survival (DSS). TLR3 did not associate significantly with survival although we found an inverse correlation between TLR3 and TLR7 immunopositivity. Hence, when TLR3 immunoexpression was negative or mild, TLR7 immunoexpression was moderate to strong, and vice versa.
CONCLUSIONS: TLR3 and TLR7 are immunoexpressed in minor salivary gland ACC. TLR7 is potentially an independent prognostic marker for recurrence rate and DSS.
Three pairs of comparable clinics (out of 22 clinics where OnTrackNY operates) based on the same region of the state and similar numbers of patients with similar demographic composition. One of each paired clinic is assigned to the intervention group by a blinded Co-I who will generate binary random variables.
OBJECTIVE: To investigate the effect of the presence or absence of fetal anomalies and soft markers diagnosed by ultrasound on positive predictive value (PPV) 21, 18 and 13 in pregnancies with a high-risk cfDNA result.
METHODS: Retrospective study including singleton pregnancies with high-risk NIPT results for common trisomies followed by invasive testing. The cases were grouped by gestational age at the time of invasive testing and by the presence or absence of fetal abnormalities or soft markers. The ultrasound was considered abnormal if at least one major defect or a soft marker was detected.
RESULTS: A total of 173 women were included. Median maternal and gestational age was 37.7 years and 14.0 weeks, respectively. CfDNA test result showed high-risk for trisomy 21 and trisomy 18 or 13 in 119 and 54 cases, respectively. The "pre-ultrasound" PPV for trisomy 21 and for trisomy 18 or 13 were 98.3% and 68.4%, respectively. In case of a high-risk result for trisomy 21 and no fetal anomalies, the PPV was 86.7% while it was 100% if there were anomalies or markers present. In the case of a high-risk result for trisomy 18 or 13, the PPV was 9.5% if the ultrasound examination was normal and 100% if the ultrasound examination was abnormal.
CONCLUSION: This study suggests that a detailed ultrasound examination performed after a cfDNA result that is high-risk for one of the common autosomal trisomies adds significantly to establishing an individualized risk assessment. This is particularly true in cases with a high-risk result for trisomies 18 or 13.
NEW MATERIAL:The benzoquinone derivative of formula I (l is 0-18; X is H, alkyl or carboxylic acid acyl; Y is phenylene, cycloalkylene or group of formula II; m is 0-3; R1 and R2 are alkyl). EXAMPLE:6-( 10-Hydroxy-10-methylundecyl )-2,3-dimethoxy-5-methyl-1,4-benzo quinone. USE:Useful as a remedy for circulatory disorder and antiallergic agent. It exhibits the electron transfer action in the succinic acid oxidase system of mitochondrion and the activity to activate the energy methabolism of a cell. It is also effective to suppress the formation of NADPH and Fe<++>-dependent lipid peroxide in the liver and brain. The agent has low toxicity and retains drug action for a long period. PREPARATION:The compound of formula IV which is one of the compound of formula I can be produced e.g. by oxidizing the compound of formula III (Z is H or OH) with an oxidizing agent such as hydrogen peroxide.
Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with electrodesiccation.